Change in PSA level poor predictor of prostate cancer
February 25th, 2011 - 5:28 pm ICT by ANIWashington, Feb 25 (ANI): Change in PSA levels over time, known as PSA velocity, is a poor predictor of prostate cancer and may lead to many unnecessary biopsies, according to researchers at Memorial Sloan-Kettering Cancer Center.
Several groups, including the National Cancer Center Network and the American Urological Association, recommend that men with high PSA velocity get a biopsy for prostate cancer, even if there are no other indicators that cancer may exist.
“We have found no evidence to support the recommendation that men with a high PSA velocity should be biopsied in the absence of other indications. Those indicators could be an elevated baseline PSA or a positive digital rectal exam (DRE),” said Andrew Vickers, Associate Attending Research Methodologist in the Department of Epidemiology and Biostatistics and lead author.
“In other words, if a man’s PSA has risen rapidly in recent years, there is no cause for concern if his total PSA level is still low and his clinical exam is normal,” he added.
The researchers studied 5,519 men aged over 55, who were participating in the prostate cancer prevention trial, with no previous prostate cancer diagnosis, normal DRE, and a baseline PSA of 3.0 ng/mL or less.
The study subkects were randomly assigned to finasteride, a drug commonly used to treat enlargement of the prostate gland, or placebo for seven years.
The team focused on men in the placebo group who were followed with yearly PSA tests. After seven years, all men in the study underwent a biopsy.
Based on these tests, the team found no important link between PSA velocity and biopsy outcome, noting that PSA alone was a much better predictor of biopsy outcome than PSA velocity.
“This study should change practice. We have previously published papers determining that PSA naturally varies from month to month and have urged men whose PSA suddenly rises to wait six weeks and repeat the test before agreeing to a needle biopsy,” said Peter T. Scardino, Chair of the Department of Surgery.
“This study provides even stronger evidence that using changes in PSA as a basis for recommendation for biopsy leads to many more unnecessary biopsies and does not help to find the more aggressive cancers that we want to find and treat,” he added.
The study is published online in the Journal of the National Cancer Institute. (ANI)
- PSA test more reliable in men taking prostate-shrinking drug - Dec 18, 2010
- New test accurately detects aggressive prostate cancer - Apr 07, 2011
- New ultrasound technology can accurately spot prostate cancer tumours - Dec 09, 2010
- Now, test to predict aggressiveness of prostate cancer - Apr 20, 2010
- Concerns over prostate cancer test - Jan 11, 2010
- Tomato compound may help prevent prostate cancer - Jul 14, 2011
- Prostate test 'can predict death risk' - Jul 09, 2010
- Simple test could save prostate cancer patients from surgery - Feb 09, 2011
- First reliable prostate cancer test could be available within months - Mar 02, 2011
- Men with long ring finger 'three times more likely to get prostate cancer' - Jul 21, 2010
- Most men unaware of blood test for prostate cancer, finds charity - Mar 01, 2011
- Scientists reveal prostate cancer's multiple personalities - Nov 04, 2010
- Why PSA levels reflect prostate cancer progression - Jan 14, 2011
- Early warning signs for prostate cancer identified - Nov 07, 2010
- Heart disease may be linked to prostate cancer - Feb 09, 2012
Tags: american urological association, andrew vickers, cancer prevention trial, digital rectal exam, kettering cancer center, memorial sloan kettering, memorial sloan kettering cancer center, national cancer center, needle biopsy, placebo group, prostate cancer, prostate cancer diagnosis, prostate cancer prevention, prostate gland, psa levels, psa tests, research methodologist, sloan kettering cancer, sloan kettering cancer center, unnecessary biopsies